Document Type

Article

Publication Date

10-1-2008

Comments

This article has been peer reviewed. It is the authors' final version prior to publication in American journal of obstetrics and gynecology Volume 199, Issue 4, October 2008, Pages 396.e1-396.e7. The published version is available at DOI: 10.1016/j.ajog.2008.06.088. Copyright © Elsevier Inc.

Abstract

OBJECTIVE: The objective of the study was to identify maternal variables predicting length of treatment for neonatal abstinence syndrome (NAS).

STUDY DESIGN: This was a retrospective cohort study of infants treated for NAS during 2000-2006 whose mothers were on methadone maintenance at delivery. Mixed-effects linear regression was used to examine the interaction of maternal and neonatal variables with length of treatment.

RESULTS: Of 204 neonates born to methadone exposed mothers, the average dose at delivery was 127 mg daily (25-340 mg) with median length of treatment 32 days (1-122 days). Trimester of initial exposure (P = .33), methadone dose at delivery (P = .198), body mass index (P = .31), antidepressant use (P = .40), cigarette use (P = .76), race (P = .78), and maternal age (P = .84) did not predict length of treatment. In the multivariate analysis, gestational age at delivery and benzodiazepine use were significant predictors of length of treatment.

CONCLUSION: Later gestational age and concomitant benzodiazepine use were associated with longer treatment.

Table 1_Demographic variables for 185 mothers enrolled in a methadone treatment program.doc (27 kB)
Table 1. Demographic variables for 185 mothers enrolled in a methadone treatment program

Table 2_Neonatal demographics and clinical variables by gestational age at birth group for 204 neonates.doc (38 kB)
Table 2. Neonatal demographics and clinical variables by gestational age at birth group for 204 neonates.

Table 3_Systematic univariate analysis of the affect of variables on length of treatment in 204 neonates treated for NAS.doc (39 kB)
Table 3. Systematic univariate analysis of the affect of variables on length of treatment in 204 neonates treated for NAS.

Table 4_Multivariate analysis of variables p 0.2 for all births (n=201).doc (31 kB)
Table 4. Multivariate analysis of variables p <0.2 for all births (n=201).

Table 5_ Multivariate subanalysis of births 32 weeks and last UDS positive for methadone only.doc (40 kB)
Table 5. Multivariate subanalysis of births >32 weeks and last UDS positive for methadone only.

Share

COinS